Siliq (brodalumab) approved by the US FDA for adult patients with moderate-to-severe plaque psoriasis
- Details
- Category: AstraZeneca
AstraZeneca's partner Valeant Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Siliq (brodalumab) injection for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.
Boehringer Ingelheim and Weill Cornell Medicine announce new collaboration to discover next generation COPD treatments
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim today announced a collaboration with Weill Cornell Medicine to identify new treatment approaches for chronic obstructive pulmonary disease (COPD) in order to develop novel treatments that could possibly halt or even reverse the progression of the disease process.
Phase III COMPASS study with Bayer's rivaroxaban (Xarelto®) shows overwhelming efficacy and meets primary endpoint early
- Details
- Category: Bayer
Bayer AG and its cooperation partner Janssen Research & Development, LLC have announced that the Phase III trial COMPASS evaluating the efficacy and safety of rivaroxaban (Xarelto®) for the prevention of major adverse cardiac events (MACE) including cardiovascular death, myocardial infarction and stroke in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) has met its primary endpoint ahead of time.
Relationship expert teams up with Pfizer to address intimacy and relationship issues for people living with chronic diseases
- Details
- Category: Pfizer
Nationally-recognized relationship expert and author, Logan Levkoff, Ph.D., has partnered with Pfizer Inc. (NYSE:PFE) to fill a void in information available to people living with chronic diseases: relationship advice. Levkoff will address the topics of relationships and intimacy for those living with a chronic condition, like rheumatoid arthritis (RA), on the newly re-launched Arthritis.com site.
Cladribine tablets significantly reduced brain atrophy in patients with multiple sclerosis
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced the publication of the results of a post hoc analysis of the Phase III CLARITY study in Multiple Sclerosis Journal. The analysis showed that Cladribine Tablets reduced the annualised rate of brain volume loss - also known as brain atrophy - compared with placebo in patients with relapsing remitting multiple sclerosis (RRMS).
Regorafenib granted priority review in the U.S. for second-line treatment of liver cancer
- Details
- Category: Bayer
Bayer announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to the supplemental New Drug Application (sNDA) for regorafenib for the second-line treatment of patients with unresectable hepatocellular carcinoma (uHCC) in the U.S.
Amgen announces Repatha® (evolocumab) significantly reduced the risk of cardiovascular events in FOURIER outcomes study
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) has announced that the FOURIER trial evaluating whether Repatha® (evolocumab) reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) met its primary composite endpoint (cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or coronary revascularization) and the key secondary composite endpoint (cardiovascular death, non-fatal MI or non-fatal stroke).
More Pharma News ...
- Roche reports good results in 2016
- Pfizer reports fourth-quarter and full-year 2016 results
- Novo Nordisk enters collaboration with University of Oxford on type 2 diabetes and invests GBP 115m in new research centre
- CUBE Challenge 2017: One Year. One Competition. One Million.
- Bristol-Myers Squibb reports fourth quarter and full year 2016 financial results
- Symbicort granted paediatric exclusivity in the US
- Abbott reports fourth-quarter 2016 results